Association between CD47 expression, clinical characteristics and prognosis in patients with advanced non‐small cell lung cancer
Óscar Arrieta(Instituto Nacional de Cancerología)
Cited by 80
Related Papers
Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non–Small Cell Lung Cancer
|JAMA Oncology|2020|153
Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With <i>ALK</i>-Positive Advanced Non–Small-Cell Lung Cancer From the Phase III CROWN Study
|Journal of Clinical Oncology|2022|133
Prevalence of pathogenic or likely pathogenic germline variants in cancer predisposition genes among selected patients with lung adenocarcinoma: The GERMLUNG study
|Lung Cancer|2024|7
Impact of KRASG12D subtype and concurrent pathogenic mutations on advanced non-small cell lung cancer outcomes
|Clinical & Translational Oncology|2023|5